RALEIGH, N.C., March 25, 2025 (GLOBE NEWSWIRE) — Marius Pharmaceuticals, a pharmaceutical company focused on developing innovative therapies for testosterone deficiency, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a new patent, strengthening the company’s intellectual property protection for its proprietary oral testosterone therapy, KYZATREX® (testosterone undecanoate) CIII Capsules.
This marks Marius Pharmaceuticals’ fifth U.S. patent, further reinforcing its leadership in the field of testosterone replacement therapy. The newly allowed patent specifically covers the company’s unique, novel formulation, which utilizes a self-emulsifying drug delivery system (SEDDS) incorporating phytosterol esters. This innovative technology enhances the…